Development of Quality of Life Questionnaire in Gastric Cancers

Phase I-II of the update of the EORTC Quality of Life Gastric module QLQ-STO22 - EORTC-QOQ-STO_22

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/02/031117

Enrollment

Registered

2021-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C169- Malignant neoplasm of stomach, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically proven as gastric adenocarcinoma with disease stages I-IV (UICC TNM 8th) 2. Patients with a gastric or junction cancer whose epicenter is located within 2 cm of the oesophagogastric junction 3. Patients receiving treatment(either currently or within the last 12 months) including a systemic treatment (chemotherapy, target agents, and immunotherapy), surgical resection, and radiotherapy or receiving supportive or palliative care 4. Patients who are willing and able to give fully informed consent to participate 5. Patients who are literate in English or Hindi

Exclusion criteria

Exclusion criteria: 1. Patients under 18 years of age 2. Patients with a concurrent malignancy 3. Cancer survivors defined as people who have completed treatment with curative intent more than 12 months ago and are now cancer-free. 4. Patients enrolled in other quality of life studies which will affect the results of the current study

Design outcomes

Primary

Measure	Time frame
Phase 1: To compile an exhaustive list of relevant QOL issues covering new treatments and different cultural perspectives from 3 sources namely, literature, patients and health care professionals. Phase 2: To develop a provisional module and to ensure that the proposed changes are in line with recommended EORTC QLG guidelines.Timepoint: 12 months	—

Secondary

Measure	Time frame
Phase 3: To administer EORTC-QLQ-C30 plus the provisional updated module to patients. Phase 4: Field test in large international groups of patientsTimepoint: Day 1 of enrolment into the study	—

Countries

Cyprus, India, Japan, Malaysia, Norway, Spain, Turkey, United Kingdom

Contacts

Public ContactDr Manjunath Nookala Krishnamurthy

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

nk.manjunath@gmail.com919920703438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026